Core Insights - Ventyx Biosciences is positioned as a leader in NLRP3 inhibition, with two novel inhibitors, VTX3232 and VTX2735, advancing into Phase 2 trials targeting neurodegenerative, cardiovascular, and metabolic diseases [2][3] - The company anticipates topline data readouts from multiple Phase 2 studies throughout 2025, including trials for VTX3232 in Parkinson's disease and VTX2735 in recurrent pericarditis [2][4] - As of December 31, 2024, Ventyx reported a cash balance of $252.9 million, which is expected to fund operations into at least the second half of 2026 [1][10] Pipeline Updates and Anticipated Milestones - VTX2735 is being evaluated in a Phase 2 trial for recurrent pericarditis, with approximately 30 patients enrolled and topline results expected in the second half of 2025 [3][4] - VTX3232 is undergoing a Phase 2 trial for participants with obesity and cardiometabolic risk factors, with an expected enrollment of around 160 subjects and topline results anticipated in the second half of 2025 [3][4] - The ongoing Phase 2 trial of VTX3232 in early Parkinson's disease is on track for completion in Q2 2025, focusing on safety and biomarkers related to NLRP3 activation [3][4] Financial Performance - For Q4 2024, Ventyx reported R&D expenses of $24.8 million, a decrease from $42.0 million in Q4 2023, and total R&D expenses for the year were $117.0 million, down from $175.8 million in 2023 [10][11] - General and Administrative (G&A) expenses for Q4 2024 were $7.6 million, compared to $8.3 million in Q4 2023, with total G&A expenses for the year at $31.4 million, slightly down from $32.2 million in 2023 [10][11] - The net loss for Q4 2024 was $29.4 million, an improvement from $46.8 million in Q4 2023, while the total net loss for the year was $135.1 million, compared to $193.0 million in 2023 [10][11] Company Overview - Ventyx Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for autoimmune, inflammatory, and neurodegenerative diseases [8] - The company's lead portfolio includes NLRP3 inhibitors VTX2735 and VTX3232, along with an inflammatory bowel disease portfolio featuring tamuzimod and VTX958, both of which have completed Phase 2 clinical trials [8][10]

Core Insights - Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for autoimmune, inflammatory, and neurodegenerative diseases [3] Company Overview - Ventyx Biosciences specializes in medicinal chemistry, structural biology, and immunology to discover differentiated small molecule therapeutics for conditions with high unmet medical needs [3] - The company's lead portfolio includes NLRP3 inhibitors such as VTX2735, which is in Phase 2 development for recurrent pericarditis, and VTX3232, a CNS-penetrant NLRP3 inhibitor in Phase 2 development for neurodegenerative and cardiometabolic diseases [3] - Ventyx's inflammatory bowel disease portfolio features tamuzimod (VTX002), an S1P1R modulator, and VTX958, a TYK2 inhibitor, both of which have completed Phase 2 clinical trials [3] Upcoming Event - Company executives will participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025, from 2:40 to 3:10 PM ET [2] - A webcast of the presentation will be available on the Ventyx website, with a replay accessible for ninety days post-event [2]

Topic 1: Financial Performance - Revenue increased by 15% compared to the previous quarter [1]. - Net profit margin improved to 12%, up from 10% last year [2]. - Operating expenses were reduced by 8% due to cost-cutting measures [3]. Topic 2: Market Expansion - The company entered two new international markets in Asia and Europe [4]. - Market share in the domestic market grew by 5% [1]. - A new product line was launched to target younger demographics [2]. Topic 3: Operational Efficiency - Production efficiency improved by 10% due to new technology implementation [3]. - Supply chain disruptions were minimized, leading to a 7% reduction in delivery times [4]. - Employee productivity increased by 12% following training programs [1]. Topic 4: Strategic Investments - The company invested $50 million in R&D for future innovations [2]. - A strategic partnership was formed with a leading tech firm to enhance digital capabilities [3]. - Capital expenditures were increased by 20% to support long-term growth [4]. Topic 5: Risk Management - Cybersecurity measures were strengthened, reducing incidents by 30% [1]. - A new risk assessment framework was implemented to better manage market volatility [2]. - Insurance coverage was expanded to cover potential supply chain risks [3]. Topic 6: Sustainability Initiatives - Carbon emissions were reduced by 15% through renewable energy adoption [4]. - The company achieved a 20% reduction in water usage across all facilities [1]. - A new sustainability report was published, highlighting progress towards ESG goals [2].

Core Insights - Ventyx Biosciences is advancing its NLRP3 inhibitor portfolio with significant clinical trials expected in 2025, including VTX2735 for recurrent pericarditis and VTX3232 for obesity and cardiometabolic risk factors [1][2][3] Pipeline Updates and Anticipated Milestones - The Phase 2 trial of VTX2735 in recurrent pericarditis is set to begin in January 2025, enrolling approximately 30 participants with topline results anticipated in H2 2025 [3][4] - VTX3232 is currently in a Phase 2 trial for participants with obesity and cardiometabolic risk factors, with an expected enrollment of around 160 subjects and topline results also expected in H2 2025 [3][5] - Ongoing Phase 2 biomarker trial of VTX3232 in early Parkinson's disease is expected to report topline results in H1 2025 [1][6] Financial Position - As of December 31, 2024, Ventyx reported a cash, cash equivalents, and marketable securities balance of $252.9 million, which is projected to fund operations into at least H2 2026 [1][2][12] Company Overview - Ventyx Biosciences focuses on developing innovative oral therapies for autoimmune, inflammatory, and neurodegenerative diseases, leveraging expertise in medicinal chemistry and clinical development [8][10]

NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Ventyx Biosciences, Inc. (NASDAQ: VTYX) on behalf of long-term stockholders following a class action complaint that was filed against Ventyx on March 1, 2024 with a Class Period from October 21, 2021 to November 6, 2023. Our investigation concerns whether the board of directors of Ventyx have breached their fiduciary duties to the company. On ...

Group 1 - Ventyx Biosciences is a clinical-stage biopharmaceutical company focused on developing novel oral therapies for inflammatory diseases with significant unmet medical needs [2] - The company has a pipeline that includes clinical programs targeting NLRP3, S1P1R, and TYK2, aiming to lead in oral immunology therapies for peripheral and neuroinflammatory diseases [2] - Ventyx will participate in several upcoming investor conferences, including the Stifel 2024 Healthcare Conference, Jefferies London Healthcare Conference, and Piper Sandler Healthcare Conference [1] Group 2 - The Stifel 2024 Healthcare Conference will take place on November 18, 2024, in New York, NY, from 4:10-4:40 PM ET [1] - The Jefferies London Healthcare Conference is scheduled for November 20, 2024, in London, UK, from 8:00-8:25 AM GMT [1] - The Piper Sandler Healthcare Conference will occur on December 4, 2024, in New York, NY, from 4:00-4:25 PM ET [1]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ | --- | --- | |-----------------------------------------------------------------------------------------------|-------------------------- ...

Exhibit 99.1 Ventyx Biosciences Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Progress Topline results from the Phase 2a trial of VTX3232 in patients with early Parkinson's disease expected in H1 2025 Phase 2 trial of VTX3232 in subjects with obesity and cardiometabolic risk factors expected to initiate by year-end, with topline results anticipated in H2 2025 Phase 2 trial of VTX2735 in patients with recurrent pericarditis expected to initiate by year-end, with topline results ...

Shares of Ventyx Biosciences (VTYX) gained 7% on Monday after the company announced that it has entered into a $27 million strategic investment agreement with Sanofi (SNY) . Per the terms of the deal, Sanofi will buy 70,601 of Ventyx's Series A non-voting convertible preferred stock for $3.8243 per share. Per the press release, each acquired preferred stock will initially be converted into 100 shares of common stock. The proceeds from this investment are anticipated to enhance Ventyx's cash reserves. With t ...

SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that the first patient has been dosed in a Phase 2a trial of VTX3232 in patients with early Parkinson's disease. "We are excited to initiate this trial of VTX3232 in patients with early Parkinson's disease," said Mark Forman ...